• Inborn errors of metabolism

Zavesca Generic Name & Formulations

General Description

Miglustat 100mg; caps.

Pharmacological Class

Glucosylceramide synthase inhibitor.

How Supplied

Caps—18, 90

Generic Availability


Zavesca Indications


Mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not feasible.

Zavesca Dosage and Administration


≥18yrs: 100mg 3 times daily; may reduce to 100mg once or twice daily if diarrhea or tremor occurs. Mild renal impairment (CrCl 50–70mL/min): 100mg twice daily. Moderate renal impairment (CrCl 30–50mL/min): 100mg once daily. Severe renal impairment: not recommended.


<18yrs: not established.

Zavesca Contraindications

Not Applicable

Zavesca Boxed Warnings

Not Applicable

Zavesca Warnings/Precautions


Perform neurological evaluations at baseline, then periodically at 6-month intervals. Reevaluate and consider discontinuation if signs/symptoms of peripheral neuropathy develop (eg, numbness, tingling). GI disease (eg, inflammatory bowel). Monitor platelets. Renal impairment. Elderly. Pregnancy. Nursing mothers: not recommended.

Zavesca Pharmacokinetics

See Literature

Zavesca Interactions


May antagonize imiglucerase.

Zavesca Adverse Reactions

Adverse Reactions

Diarrhea, weight loss, tremor, flatulence, abdominal pain, GI disturbances, weakness, headache, dizziness, paresthesia, cramps, vision problems, thrombocytopenia, back pain, dry mouth, menstrual changes; reduced spermatogenesis, peripheral neuropathy.

Zavesca Clinical Trials

See Literature

Zavesca Note

Not Applicable

Zavesca Patient Counseling

See Literature